In Vitro Approaches for the Assessment of Serpin Polymerization.

In Vitro Approaches for the Assessment of Serpin Polymerization.
复制标题

评估丝氨酸蛋白酶抑制剂聚合的体外方法。

DOI:
10.1007/978-1-4939-8645-3_6
复制
发表时间:
2018
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
通讯作者:
Elliston ELK
Elliston ELK
中科院分区:
--
文献类型:
--
作者:
Elliston ELK

文献摘要

参考文献

相似文献

丝氨酸蛋白酶抑制剂聚合是丝氨酸蛋白酶抑制剂单体端对端有序聚集成直链无支链的结果。这种分子状态的变化代表了几种具有病理性功能获得和功能丧失表型的构象疾病的基础,称为丝氨酸蛋白酶抑制剂病。因此,能够定量和表征聚合物形成的工具对于在这种病理生理学背景下研究丝氨酸蛋白酶抑制剂行为是重要的。这些方法依赖于分子变化的不同表现:聚合-分子量增加的分子的产生-伴随着组成亚基的结构重排。不同的方法可能是适当的,这取决于测量是在静态样品上进行的,例如组织或细胞培养提取物,还是在时间分辨实验中进行的,通常使用在体外不稳定条件下人工诱导的聚合物。在前一类中,我们描述了聚丙烯酰胺电泳,Western印迹,ELISA和负染电子显微镜的应用,在后一类中,福斯特共振能量转移和荧光光谱使用环境敏感的探针。
Serpin polymerization is the result of end-to-end ordered aggregation of serpin monomers into linear unbranched chains. This change in molecular state represents the basis of several conformational diseases with pathological gain-of-function and loss-of-function phenotypes, termed serpinopathies. Tools that enable quantification and characterization of polymer formation are therefore important to the study of serpin behavior in this pathophysiological context. Such methods rely on different manifestations of molecular change: polymerization—the generation of molecules with increasing molecular weight—is accompanied by concomitant structural rearrangements in the constituent subunits. Different approaches may be appropriate dependent on whether measurements are made on static samples, such as tissue or cell culture extracts, or in time-resolved experiments, often undertaken using polymers artificially induced under in vitro destabilizing conditions. In the former category, we describe the application of polyacrylamide electrophoresis, Western blot, ELISA, and negative-stain electron microscopy and in the latter category, Förster resonance energy transfer and fluorescence spectroscopy using environment-sensitive probes.
DOI: 10.1016/j.bpj.2009.07.057
发表时间: 2009-10-21
影响因子: 3.4
作者:
Chiou, Albert;Haeggloef, Peter;Klenerman, David
通讯作者: Klenerman, David
使用新型单克隆抗体表征潜伏期与 α1-抗胰蛋白酶聚合的关联
DOI: --
发表时间: 2015
影响因子: 4
作者:
L. Tan;J. Pérez;M. Mela;E. Miranda;K. Burling;Farshid N. Rouhani;D. Demeo;I. Haq;J. Irving;A. Ordóñez;Jennifer A. Dickens;M. Brantly;S. Marciniak;G. Alexander;B. Gooptu;D. Lomas
通讯作者: D. Lomas
纤溶酶原激活剂抑制剂-1* 的聚合
DOI: 10.1074/jbc.m010631200
发表时间: 2001
期刊: The Journal of Biological Chemistry
影响因子: --
作者:
Aiwu Zhou;R. Faint;P. Charlton;T. Dafforn;R. Carrell;D. Lomas
通讯作者: D. Lomas
DOI: 10.1038/nmeth.2019
发表时间: 2012-06-28
期刊: NATURE METHODS
影响因子: 48
作者:
Schindelin, Johannes;Arganda-Carreras, Ignacio;Frise, Erwin;Kaynig, Verena;Longair, Mark;Pietzsch, Tobias;Preibisch, Stephan;Rueden, Curtis;Saalfeld, Stephan;Schmid, Benjamin;Tinevez, Jean-Yves;White, Daniel James;Hartenstein, Volker;Eliceiri, Kevin;Tomancak, Pavel;Cardona, Albert
通讯作者: Cardona, Albert
纤溶酶原激活剂抑制剂-1 聚合物,通过灭活两亲性有机化学配体诱导。
DOI: --
发表时间: 2003
影响因子: 4.1
作者:
Katrine Pedersen;A. P. Einholm;A. Christensen;L. Schack;T. Wind;J. Kenney;P. Andreasen
通讯作者: P. Andreasen